AMENDMENTS TO THE CLAIMS

Please amend claims 15 and 26 and cancel claim 18, as shown below. A complete listing of the claims, including their current status, is provided below:

1-14 (cancelled)

- (Currently amended) A method for inhibiting an immune reaction, said method comprising administering a peptide comprising the amino acid sequence of:
- i) Gly-Ala-His-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg (SEO ID NO:1) or a conservative amino acid substitution thereof at a residue position other than 4, 5, 6, 9, 10 or 11;
- ii) Gly-Ala-Ala-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg (SEQ ID NO:7) or a conservative amino acid substitution thereof at a residue position other than 4,5, 6, 9, 10 or 11;
- iii) Gly-Ala-His-Trp-Gln-Phe-Ala-Ala-Leu-Thr-Val-Arg (SEQ ID NO:8) or a conservative amino acid substitution thereof at a residue position other than 4,5, 6, 9, 10 or 11; and
- iv) Gly-Ala-His-Trp-Gin-Phe-Asn-Ala-Leu-Thr-Val-Ala (SEQ ID NO:9) or a conservative amino acid substitution thereof at a residue position other than 4,5, 6, 9, 10 or 11,

wherein the peptide which selectively binds hyaluronic acid and wherein said administering inhibits an immune reaction..

- 1 (Original) The method of claim 45, wherein the immune reaction is cutaneous.
- (Original) The method of claim 15, wherein the peptide inhibits leukocyte infiltration.

18-25 (cancelled)

Attorney Docket No. SWMC-001DIV

U

- 26. (currently amended) The method of claim 15; wherein said method comprises administering:
 - a carrier material; and
 - a said peptide the amino acid sequence of:
- i) Gly-Ala His-Trp-Gln-Phe-Asn-Ala-Leu-Thr-Val-Arg-or-a-conservative amino acid-substitution-thereof;
- ii) ----- Gly-Ala-Ala-Trp-Gln-Phe-Asn-Ala-Leu Thr-Val-Arg or a conservative amino acid substitution thereof;
- iii) Gly-Ala-His-Trp-Gln-Pho-Ala Ala Leu-Thr-Val-Arg or a conservative amino acid substitution thereof; or
- iv)—Gly-Ala-l·lis-Trp-Gla-Phe Asa Ala-Leu Thr Val Ala or a conservative amino acid-substitution thereof

to a subject with an immune reaction.